Clinical Trials Logo

Clinical Trial Summary

COVID-19 is a novel coronavirus infection caused by respiratory droplets and contact transmission. With the spread of the epidemic, it has become a serious threat to global public health. China has launched a full range of vaccination including the third dose of homologous and sequential booster immunization. To further improve COVID-19 vaccine immunization strategy, we start the clinic research about sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine in Zhejiang province.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05373030
Study type Interventional
Source Zhejiang Provincial Center for Disease Control and Prevention
Contact Hangjie Zhang, phD
Phone +86-13634159682
Email [email protected]
Status Recruiting
Phase Phase 4
Start date May 14, 2022
Completion date June 30, 2023